Jan Mueller-Brand
90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas
Gerster-Gilliéron K, Forrer F, Maecke H, Mueller-Brand J, Merlo A, Cordier D. 90Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas. J Nucl Med 2015; 56:1748-51.
20.08.201590Y-DOTATOC as a Therapeutic Option for Complex Recurrent or Progressive Meningiomas
20.08.2015J Nucl Med 2015; 56:1748-51
Gerster-Gilliéron Karine, Forrer Flavio, Maecke Helmut, Mueller-Brand Jan, Merlo Adrian, Cordier Dominik
Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas
Forrer F, Oechslin-Oberholzer C, Campana B, Herrmann R, Maecke H, Mueller-Brand J, Lohri A. Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas. J Nucl Med 2013; 54:1045-52.
09.04.2013Radioimmunotherapy with 177Lu-DOTA-rituximab: final results of a phase I/II Study in 31 patients with relapsing follicular, mantle cell, and other indolent B-cell lymphomas
09.04.2013J Nucl Med 2013; 54:1045-52
Forrer Flavio, Oechslin-Oberholzer Catharina, Campana Benedetta, Herrmann Richard, Maecke Helmut R, Mueller-Brand Jan, Lohri Andreas
Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors
Forrer F, Waldherr C, Maecke H, Mueller-Brand J. Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors. Anticancer Res 2006; 26:703-7.
01.01.2006Targeted radionuclide therapy with 90Y-DOTATOC in patients with neuroendocrine tumors
01.01.2006Anticancer Res 2006; 26:703-7
Forrer Flavio, Waldherr Christian, Maecke Helmut R, Mueller-Brand Jan
Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC
Forrer F, Uusijärvi H, Storch D, Maecke H, Mueller-Brand J. Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC. J Nucl Med 2005; 46:1310-6.
01.08.2005Treatment with 177Lu-DOTATOC of patients with relapse of neuroendocrine tumors after treatment with 90Y-DOTATOC
01.08.2005J Nucl Med 2005; 46:1310-6
Forrer Flavio, Uusijärvi Helena, Storch Daniel, Maecke Helmut R, Mueller-Brand Jan